# Efzofitimod PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/efzofitimod

> The next catalyst for efzofitimod, sponsored by aTYR PHARMA INC (ATYR), is its topline data readout, Q1 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, quarter only, exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What is the next FDA catalyst for efzofitimod?

The next catalyst for efzofitimod, sponsored by aTYR PHARMA INC (ATYR), is its topline data readout, Q1 2027. Press release filed with the SEC (EX-99): "Topline results are expected in the first quarter of 2027." [Calendar and source filings](https://sec-api.dev/pdufa/efzofitimod)

Source: Press release filed with the SEC (EX-99), accession 0001339970-26-000051, https://www.sec.gov/Archives/edgar/data/1339970/000133997026000051/atyr-ex99_1.htm (retrieved 2026-11-12). Last confirmed 2026-08-07. Cite: https://sec-api.dev/pdufa/efzofitimod#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | efzofitimod |
| Codes | ATYR1923 |
| Sponsor | aTYR PHARMA INC (ATYR) https://sec-api.dev/companies/atyr/catalysts |
| Indications | [pulmonary sarcoidosis](https://sec-api.dev/indications/pulmonary-sarcoidosis), Interstitial Lung Disease |
| Modality |  |
| FDA designations | breakthrough, fast track, orphan |

## Timeline

### Sep 2022: trial start

- Status: completed. Date confidence: month.
- First seen 2024-12-23, last confirmed 2025-08-07.
- SEC Form 10-Q (accession 0001339970-25-000009): "In September 2022, we dosed the first patient in the study." https://www.sec.gov/Archives/edgar/data/1339970/000133997025000009/atyr-20250630.htm
- SEC Form 10-Q (accession 0000950170-25-065640): "In September 2022, we dosed the first patient in the study." https://www.sec.gov/Archives/edgar/data/1339970/000095017025065640/atyr-20250331.htm
- SEC Form 10-K (accession 0000950170-25-038888): "In September 2022, we dosed the first patient in the study." https://www.sec.gov/Archives/edgar/data/1339970/000095017025038888/atyr-20241231.htm
- SEC prospectus (424B) (accession 0000950170-24-139642): "In September 2022, we dosed the first patient in the study." https://www.sec.gov/Archives/edgar/data/1339970/000095017024139642/atm_prosupp_dec_2024.htm

### Feb 2023: trial start

- Status: completed. Date confidence: month.
- First seen 2024-12-23, last confirmed 2026-11-06.
- SEC prospectus (424B) (accession 0001339970-26-000083): "In February 2023, Kyorin dosed the first patient in Japan in the EFZO-FIT study which triggered a $10.0 million milestone payment to us." https://www.sec.gov/Archives/edgar/data/1339970/000133997026000083/atm_prosupp_nov_2026.htm
- SEC Form 10-Q (accession 0001339970-26-000033): "In February 2023, Kyorin dosed the first patient in Japan in the EFZO-FIT study which triggered a $10.0 million milestone payment to us." https://www.sec.gov/Archives/edgar/data/1339970/000133997026000033/atyr-20260331.htm
- SEC Form 10-K (accession 0001339970-26-000008): "In February 2023, Kyorin dosed the first patient in Japan in the EFZO-FIT study which triggered a $10.0 million milestone payment to us." https://www.sec.gov/Archives/edgar/data/1339970/000133997026000008/atyr-20251231.htm
- SEC Form 10-Q (accession 0001193125-25-269587): "In February 2023, Kyorin dosed the first patient in Japan in the EFZO-FIT study which triggered a $10.0 million milestone payment to us." https://www.sec.gov/Archives/edgar/data/1339970/000119312525269587/atyr-20250930.htm
- SEC Form 10-Q (accession 0001339970-25-000009): "In February 2023, Kyorin dosed the first patient in Japan in the EFZO-FIT study which triggered a $10.0 million milestone payment to us." https://www.sec.gov/Archives/edgar/data/1339970/000133997025000009/atyr-20250630.htm
- SEC Form 10-Q (accession 0000950170-25-065640): "In February 2023, Kyorin dosed the first patient in Japan in the EFZO-FIT study which triggered a $10.0 million milestone payment to us." https://www.sec.gov/Archives/edgar/data/1339970/000095017025065640/atyr-20250331.htm
- SEC Form 10-K (accession 0000950170-25-038888): "In February 2023, Kyorin dosed the first patient in Japan in the EFZO-FIT study which triggered a $10.0 million milestone payment to us." https://www.sec.gov/Archives/edgar/data/1339970/000095017025038888/atyr-20241231.htm
- SEC Form 10-K (accession 0000950170-25-038888): "Additionally, in February 2023, Kyorin dosed the first patient in Japan in the EFZO-FIT study which triggered a $10.0 million milestone payment to us." https://www.sec.gov/Archives/edgar/data/1339970/000095017025038888/atyr-20241231.htm
- SEC prospectus (424B) (accession 0000950170-24-139642): "In February 2023, Kyorin dosed the first patient in Japan in the EFZO-FIT study which triggered a $10.0 million milestone payment to us." https://www.sec.gov/Archives/edgar/data/1339970/000095017024139642/atm_prosupp_dec_2024.htm

### Oct 2023: trial start

- Status: completed. Date confidence: month.
- First seen 2024-12-23, last confirmed 2024-12-23.
- SEC prospectus (424B) (accession 0000950170-24-139642): "The study was initiated in the third quarter of 2023, and in October 2023, we dosed the first patient in this study." https://www.sec.gov/Archives/edgar/data/1339970/000095017024139642/atm_prosupp_dec_2024.htm

### Q2 2025: interim data readout

- Status: scheduled. Date confidence: quarter.
- First seen 2024-12-23, last confirmed 2025-05-07.
- Press release filed with the SEC (EX-99) (accession 0000950170-25-065611): "Interim data from the study are expected in the second quarter of 2025 and will focus on skin assessments measured at baseline and week 12 in approximately eight patients, including patients in both the efzofitimod and placebo arms." https://www.sec.gov/Archives/edgar/data/1339970/000095017025065611/atyr-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-038703): "Interim data from the study are expected in the second quarter of 2025 and will focus on skin assessments measured at baseline and week 12 in approximately 8 patients, including patients on drug and placebo." https://www.sec.gov/Archives/edgar/data/1339970/000095017025038703/atyr-ex99_1.htm
- SEC Form 10-Q (accession 0000950170-25-065640): "Based on current enrollment projections, we expect to report interim data from the study in the second quarter of 2025." https://www.sec.gov/Archives/edgar/data/1339970/000095017025065640/atyr-20250331.htm
- SEC Form 10-K (accession 0000950170-25-038888): "Based on current enrollment projections, we expect to report interim data from the study in the second quarter of 2025." https://www.sec.gov/Archives/edgar/data/1339970/000095017025038888/atyr-20241231.htm
- SEC prospectus (424B) (accession 0000950170-24-139642): "Based on current enrollment projections, we expect to report interim data from the study in the second quarter of 2025." https://www.sec.gov/Archives/edgar/data/1339970/000095017024139642/atm_prosupp_dec_2024.htm

### June 25, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Pulmonary Sarcoidosis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05415137 (Efficacy and Safety of Intravenous Efzofitimod in Patients With Pulmonary Sarcoidosis): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-06-25 (ACTUAL); Lead Sponsor aTyr Pharma, Inc.." https://clinicaltrials.gov/study/NCT05415137

### Q3 2025: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: pulmonary sarcoidosis.
- First seen 2025-03-13, last confirmed 2025-05-07.
- Press release filed with the SEC (EX-99) (accession 0000950170-25-065611): "Topline data from Phase 3 EFZO-FIT study of efzofitimod in pulmonary sarcoidosis on track for the third quarter of 2025." https://www.sec.gov/Archives/edgar/data/1339970/000095017025065611/atyr-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-065611): "On track to announce topline data in the third quarter of 2025 from the global pivotal Phase 3 EFZO-FIT study to evaluate the efficacy and safety of efzofitimod in patients with pulmonary sarcoidosis." https://www.sec.gov/Archives/edgar/data/1339970/000095017025065611/atyr-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-038703): "Topline data from Phase 3 EFZO-FIT study of efzofitimod in pulmonary sarcoidosis expected in the third quarter of 2025." https://www.sec.gov/Archives/edgar/data/1339970/000095017025038703/atyr-ex99_1.htm
- SEC Form 10-K (accession 0000950170-25-038888): "Topline data from the EFZO-FIT study are anticipated in the third quarter of 2025, and our strategy for the advancement of efzofitimod includes submitting data from the EFZO-FIT study to the FDA, which we expect to serve as the basis for U.S. regulatory approval." https://www.sec.gov/Archives/edgar/data/1339970/000095017025038888/atyr-20241231.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-038703): "Topline data from the study are expected in the third quarter of 2025." https://www.sec.gov/Archives/edgar/data/1339970/000095017025038703/atyr-ex99_1.htm

### April 2026: primary completion

- Status: delayed. Date confidence: month. Stage: 2. Indication: Interstitial Lung Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05892614 (Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-04 (ESTIMATED); Lead Sponsor aTyr Pharma, Inc.." https://clinicaltrials.gov/study/NCT05892614

### August 7, 2026: earnings report

- Status: completed. Date confidence: exact.
- First seen 2026-08-07, last confirmed 2026-08-07.
- Press release filed with the SEC (EX-99) (accession 0001339970-26-000051): "Sr. Director, Investor Relations and Public Affairs adunston@atyrpharma.com aTyr Pharma Announces Second Quarter 2026 Results, Program Prioritization and Corporate Restructuring to Support Efzofitimod Program in ILD" https://www.sec.gov/Archives/edgar/data/1339970/000133997026000051/atyr-ex99_1.htm

### Q1 2027: topline data readout

- Status: scheduled. Date confidence: quarter.
- First seen 2026-08-07, last confirmed 2026-08-07.
- Press release filed with the SEC (EX-99) (accession 0001339970-26-000051): "Topline results are expected in the first quarter of 2027." https://www.sec.gov/Archives/edgar/data/1339970/000133997026000051/atyr-ex99_1.htm
- SEC Form 10-Q (accession 0001339970-26-000053): "Topline data are anticipated in the first quarter of 2027." https://www.sec.gov/Archives/edgar/data/1339970/000133997026000053/atyr-20260630.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/efzofitimod.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Efzofitimod PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/efzofitimod

```bibtex
@misc{secapidev_pdufa_efzofitimod_20261116,
  title        = {Efzofitimod PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/efzofitimod}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_efzofitimod_20261116","title":"Efzofitimod PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/efzofitimod","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
